Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.
03 Oct 2016
Continuing to execute strategy on core focus
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Continuing to execute strategy on core focus
aap Implantate AG (AAQ1:ETR) | 0 0 5.5% | Mkt Cap: 50.5m
- Published:
03 Oct 2016 -
Author:
Dr Linda Pomeroy -
Pages:
2
Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.